ATE333287T1 - Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten - Google Patents
Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonistenInfo
- Publication number
- ATE333287T1 ATE333287T1 AT99922536T AT99922536T ATE333287T1 AT E333287 T1 ATE333287 T1 AT E333287T1 AT 99922536 T AT99922536 T AT 99922536T AT 99922536 T AT99922536 T AT 99922536T AT E333287 T1 ATE333287 T1 AT E333287T1
- Authority
- AT
- Austria
- Prior art keywords
- prophylaxis
- treatment
- demyelinating diseases
- autoimmune demyelinating
- fas
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14953098 | 1998-05-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE333287T1 true ATE333287T1 (de) | 2006-08-15 |
Family
ID=15477161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99922536T ATE333287T1 (de) | 1998-05-29 | 1999-05-28 | Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten |
Country Status (6)
Country | Link |
---|---|
US (1) | US6759041B1 (de) |
EP (1) | EP1082967B1 (de) |
AT (1) | ATE333287T1 (de) |
CA (1) | CA2333880A1 (de) |
DE (1) | DE69932434D1 (de) |
WO (1) | WO1999062554A1 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19959049A1 (de) * | 1999-12-07 | 2001-06-28 | Deutsches Krebsforsch | Kombination von Verbindungen, welche die biologischen Wirkungen von TNF-alpha und CD95L hemmen |
US7848848B2 (en) * | 2006-04-28 | 2010-12-07 | Freeslate, Inc. | Robotic station for capturing both image and weight of a sample |
US7875589B2 (en) | 2006-12-11 | 2011-01-25 | The Board Of Trustees Of The Leland Stanford Junior University | Alpha B-crystallin as a therapy for rheumatoid arthritis |
US8771689B2 (en) | 2006-12-11 | 2014-07-08 | The Board Of Trustees Of The Leland Stanford Junior University | Alpha B-crystallin as a therapy for ischemia or inflammation |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63230629A (ja) * | 1987-03-19 | 1988-09-27 | Microbial Chem Res Found | 自己免疫疾患予防治療剤 |
JPH09503672A (ja) * | 1993-10-14 | 1997-04-15 | イミュネックス・コーポレーション | Fas拮抗剤とその利用 |
US5830469A (en) * | 1993-10-14 | 1998-11-03 | Immunex Corporation | Fas antagonists and uses thereof |
JPH08127594A (ja) * | 1993-11-10 | 1996-05-21 | Mochida Pharmaceut Co Ltd | Fas抗原に結合する新規蛋白質およびそれをコードするDNA |
IL114615A0 (en) | 1995-07-16 | 1995-11-27 | Yeda Res & Dev | Modulators of the function of fas receptors and other proteins |
NZ311174A (en) * | 1995-06-30 | 1999-04-29 | Mochida Pharm Co Ltd | Anti-fas ligand antibody which suppresses fas ligand-induced apoptosis in cells and method of assaying a fas ligand using the anti-fas ligand antibody |
US6399327B1 (en) * | 1995-07-16 | 2002-06-04 | Yeda Research And Development Co. Ltd. | Modulators of the function of FAS receptors and other proteins |
AU2527397A (en) * | 1996-03-13 | 1997-10-01 | Protein Design Labs, Inc. | Fas ligand fusion proteins and their uses |
AU2650597A (en) | 1996-05-02 | 1997-11-26 | Mochida Pharmaceutical Co., Ltd. | Novel fas antigen derivatives |
CA2264968A1 (en) * | 1996-09-02 | 1998-03-12 | Sumitomo Electric Industries, Ltd. | Humanized immunoglobulin reacting specifically with fas ligand or active fragments thereof and region inducing apoptosis originating in fas ligand |
ATE273713T1 (de) * | 1996-10-31 | 2004-09-15 | Mochida Pharm Co Ltd | Fas-antagonist für die prophylaxe oder therapie von gvhd |
US6544523B1 (en) * | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
US6358508B1 (en) * | 1997-06-11 | 2002-03-19 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR9 |
EP1033910A4 (de) | 1997-10-10 | 2004-11-24 | Cytovia Inc | Dipeptid-apoptose-inhibitoren und deren verwendung |
US6184210B1 (en) * | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
US6098631A (en) * | 1998-01-21 | 2000-08-08 | The Regents Of The University Of Michigan | Compositions and methods for treating autoimmune disease |
-
1999
- 1999-05-28 CA CA002333880A patent/CA2333880A1/en not_active Abandoned
- 1999-05-28 US US09/701,486 patent/US6759041B1/en not_active Expired - Fee Related
- 1999-05-28 AT AT99922536T patent/ATE333287T1/de not_active IP Right Cessation
- 1999-05-28 DE DE69932434T patent/DE69932434D1/de not_active Expired - Lifetime
- 1999-05-28 WO PCT/JP1999/002818 patent/WO1999062554A1/ja active IP Right Grant
- 1999-05-28 EP EP99922536A patent/EP1082967B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69932434D1 (de) | 2006-08-31 |
EP1082967B1 (de) | 2006-07-19 |
EP1082967A1 (de) | 2001-03-14 |
EP1082967A4 (de) | 2001-11-07 |
US6759041B1 (en) | 2004-07-06 |
WO1999062554A1 (fr) | 1999-12-09 |
CA2333880A1 (en) | 1999-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69805973D1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase | |
DE60133029D1 (de) | Mittel zur prävention oder behandlung von psoriasi | |
DE69736441D1 (de) | Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen | |
UA26213C2 (uk) | Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові | |
ATE201138T1 (de) | Verwendung von anti-mikrotubuli mitteln zur behandlung und prophylaxe der multiplen sclerose | |
EA200200208A1 (ru) | Синергитическая композиция | |
DE69507029D1 (de) | Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten | |
ATE235481T1 (de) | Substituierte benzopyranderivate zur behandlung von entzündungen | |
DE69509544D1 (de) | Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten | |
DE69034148D1 (de) | Kombinationstherapie zur Prophylaxe und/oder Behandlung von gutartiger prostatischer Hyperplasie | |
DK0705100T3 (da) | Terapeutiske substituerede guanidiner | |
ATE211384T1 (de) | Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera | |
ATE201597T1 (de) | Verabreichung von riluzol zur behandlung von neuro-aids | |
DK0679393T3 (da) | Pharmaceutisk præparat til behandling af osteoporose indeholdende xanthohumol | |
NZ516513A (en) | Nitric oxide donors for inducing neurogenesis | |
FI972308A0 (fi) | 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi | |
ATE469907T1 (de) | Triptolid-analoga zur behandlung von autoimmunkranheiten und entzündungen | |
DE69814444D1 (de) | Kombination von angiotensing-convertin-enzyme hemmern mit diuretikum zur behandlung von störungen der mikrozirkulation | |
DE69405919D1 (de) | Zusammensetzungen zur Behandlung von Keratinfasern | |
DE69918972D1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
DE69227696D1 (de) | Zusammensetzungen zur behandlung von hiv-infektionen | |
DE69420229D1 (de) | Pharmazeutische Zusammensetzung zur Behandlung von AIDS | |
DE3854121D1 (de) | Arzneimittelzusammensetzungen zur behandlung von psoriasis. | |
ATE333287T1 (de) | Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten | |
DE3679781D1 (de) | Verwendung von zusammensetzungen fuer die behandlung und die prophylaxe von epithelialer zerstoerung. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |